Blood, in-vivo tests may get better with IT at BASi

WEST LAFAYETTE, INDIANA: BASi (Bioanalytical Systems, Inc.) is collaborating with Data Sciences International (DSI), a biomedical research company focused on preclinical systems physiology and pharmacology, to conduct a study combining BASi's Culex-L automated sampling system with DSI's newest large animal telemetry technology, PhysioTel Digital.

As per a statement shared, this study is tagged as 'first-of-its-kind' and 'pivotal' by the company.

In this study, BASi's Culex-L automated in vivo sampling system will simultaneously collect biological samples at pre-programmed intervals while DSI telemetry devices will collect heart rate, blood pressure and other cardiovascular information. Previously, gathering all of these types of data required two separate experiments and only discontinuous data collection was possible.

"By combining Culex with telemetry, the automated blood sampling and telemetry (ABST) system will reduce costs, the number of test subjects, subject stress levels, and deliver better data, which will lead to better decisions," said Jacqueline M. Lemke, interim president & CEO and CFO of BASi. "This study lays the groundwork for additional safety pharmacology studies that further complement BASi's long-established and well-respected CRO services expertise."

"We're responding to customers' requests for more and better pharmacokinetic data. We know how important these data are for early decision-making in the drug discovery process. Combining DSI's telemetry with BASi's automation is a natural fit," said Dr. Dusty Sarazan, Vice President and CSO of DSI.